Discussion and Conclusion
Median overall survival for recurrent ovarian cancer is reported to be 46 months[15] .Here, we present a rare case of recurrent ovarian cancer with a survival period of 122 months. The treatment with antitumor Chinese medicine injection as maintenance therapy surprisingly resulted in a durable tumor control. In addition, no adverse reactions or tumor recurrence have been reported. Antitumor Chinese medicine injection has been widely used as a combination therapy for ovarian cancer in China to improve clinical efficacy, reduce side effects of chemotherapy and improve patients ’quality of life[16] .A recent study showed that matrine in ovarian cancer mainly through the regulation of ERK/JNK, PI3K/AKT, NF-κB pathway to play its anti-proliferation, pro-apoptosis mechanism to achieve anti-tumor purposes[17] .Another study showed that Aidi injection can reduce the expression levels of CEA, CA153 and HE4 in ovarian cancer markers in rats, regulate PI3K/mTOR signaling pathway to inhibit ovarian cancer cell proliferation and induce apoptosis[18] .
This patient was diagnosed with high-grade serous ovarian cancer. Approximately 70% of epithelial ovarian cancer recurred within 1-2 years of diagnosis[19] .In this case, Aidi combined with Kushen provides a safe and effective method, and we believe that these two traditional Chinese medicine injections may participate in antitumor therapy. Although the exact mechanism of Aidi combined with Kushen in preventing recurrence and metastasis of ovarian cancer is not fully understood, it has demonstrated satisfactory clinical effects and no significant adverse reactions. However, Further studies are needed to determine the safety and efficacy of Aidi combined with compound Sophora flavescens as a viable treatment regimen for ovarian cancer recurrence and metastasis.